secwatch.observer — SEC 8-K summary
======================================

Issuer:     OnKure Therapeutics, Inc. (OKUR)
CIK:        0001637715
Form:       8-K
Filed at:   2024-11-07T23:59:59+00:00
Accession:  0000950170-24-123265
Event type: other_material
Sentiment:  negative
Materiality: 0.65
Item codes: 4.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Legacy OnKure posts $35.2M net loss in 9mo; auditor switched to KPMG post-merger
--------------------------------------------------------------------------------

- Net loss of $35.2M for nine months ended Sep 30, 2024, vs $25.9M in prior year.
- Cash and equivalents $8.0M as of Sep 30, 2024; accumulated deficit $137.3M.
- Ernst & Young dismissed as auditor; KPMG engaged as new independent registered public accounting firm.
- Merger with Reneo closed Oct 4, 2024; management expects combined cash to fund operations for at least 12 months.
- Convertible notes payable of $6.0M issued in 2024, net of $142k issuance costs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1637715/000095017024123265/0000950170-24-123265-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1637715/000095017024123265/okur-20241107.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-123265

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer